NIH Library Makes MetaCore Accessible Site Wide
ST. JOSEPH, Mich., Sept. 29 /PRNewswire/ — GeneGo, Inc., the leading systems biology tools company, announced today that the NIH Library at Bethesda has licensed MetaCore for NIH staff. MetaCore is an easy to use pathway analysis and data mining tool that provides users with fast easy access to up to date pertinent systems biology related information. Researchers can run simple searches as well as very specific Boolean queries and have answers in seconds or minutes rather than weeks and months using traditional methods. MetaCore also has unique tools for enrichment and interactome analysis of experimental data from gene expression, proteomic, and micro RNA to assay data as well as biomarker studies. Medha Bhagwat, Biomedical Informationist at the NIH Library, is the contact person for information about MetaCore access.
“Many NIH departments have been customers of GeneGo for years, and it is nice to provide broader access to NIH researchers through the library,” said Julie Bryant, GeneGo’s VP of Business development. “Libraries provide a central location for researchers, bench scientists, oncologists, neurologists, bioinformaticians, and core labs to go for systems biology and pathway analysis tools. We will continue to work with the NIH to provide high quality support and training.”
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.4(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecule compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company’s web site at www.genego.com.
Nothing in this press release constitutes or should be inferred to be an endorsement or recommendation of any product, service, or enterprise by the National Institutes of Health, any other agency of the United States Government, or any employee of the United States Government.
SOURCE GeneGo, Inc.